Moreover, because the crosstalk in signaling networks of these targets may affect the efficacy of the novel agents, effective treatments should not only target TA in cancer cells but should also be aimed at modulating the proper function of the ATRX/DAXX/H3.3 complex to destroy tumor cells. Here, DAXX is linked to cancer.